OptiLight by Lumenis is the first and only intense pulsed light treatment that is approved by the United States Food and Drug Administration for dry eye disease due to meibomian gland dysfunction.
Using precise, gentle pulses of light, it reduces inflammation, improves meibomian gland function, and decreases demodex mites and bacteria that worsen symptoms.
The quick, non-invasive sessions enhance tear film stability; relieve burning, itching and redness; and improve ocular comfort and vision quality. With no downtime and a proven safety profile, OptiLight offers eye care professionals a clinically validated, technology-driven solution that treats the underlying cause of chronic dry eye – delivering long-lasting relief and healthier eyes for patients.
Contact: Lumenis (AUS) 1800 586 364 or (NZ) 0800 239 015
